Cargando…
Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer
The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression...
Autores principales: | Gomes, Inês, de Almeida, Bernardo P., Dâmaso, Sara, Mansinho, André, Correia, Inês, Henriques, Sara, Cruz-Duarte, Raquel, Vilhais, Guilherme, Félix, Pedro, Alves, Patrícia, Corredeira, Patrícia, Barbosa-Morais, Nuno L., Costa, Luis, Casimiro, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233807/ https://www.ncbi.nlm.nih.gov/pubmed/32477461 http://dx.doi.org/10.18632/oncotarget.27576 |
Ejemplares similares
-
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
por: Demchenko, Yulia N., et al.
Publicado: (2014) -
NFkB Pathway and Hodgkin Lymphoma
por: Jardin, Fabrice
Publicado: (2022) -
The Roadmap of RANKL/RANK Pathway in Cancer
por: Casimiro, Sandra, et al.
Publicado: (2021) -
A critical role for the NFkB pathway in multiple myeloma
por: Demchenko, Yulia N., et al.
Publicado: (2010) -
NFkB and Nrf2 in esophageal epithelial barrier function
por: Chen, Hao, et al.
Publicado: (2013)